Omnicell (OMCL) Notes Payables (2021 - 2025)
Omnicell's (OMCL) quarterly Notes Payables came in at $174.8 million in Q2 2025, little changed quarter-over-quarter from $174.6 million in Q1 2025.
Analysis
Omnicell (OMCL) Notes Payables (2021 - 2025) Analysis & Trends
Omnicell (OMCL) has reported Notes Payables for 4 consecutive years, with $174.8 million the latest figure, recorded in Q2 2025.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $174.8 million in Q2 2025; TTM through Jun 2025 was $174.8 million, a N/A change from a year earlier, with the FY2024 full-year figure at $174.3 million, changed N/A from the prior year.
- Notes Payables was $174.8 million for Q2 2025 at Omnicell, roughly flat from $174.6 million in the prior quarter.
- Over five years, Notes Payables peaked at $572.0 million in Q3 2024 and troughed at $174.3 million in Q4 2024.
- A 4-year average of $358.0 million and a median of $331.5 million in 2021 frame the typical range for Notes Payables.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 174.80 Mn |
| Mar 31, 2025 | 174.56 Mn |
| Dec 31, 2024 | 174.32 Mn |
| Sep 30, 2024 | 572.00 Mn |
| Mar 31, 2022 | 564.27 Mn |
| Dec 31, 2021 | 488.15 Mn |